{"id":37554,"date":"2026-08-10T11:57:09","date_gmt":"2026-08-10T11:57:09","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=37554"},"modified":"2026-08-10T11:57:09","modified_gmt":"2026-08-10T11:57:09","slug":"innate-pharma-partners-with-sobi-on-lacutamab","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","title":{"rendered":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30e9\u30af\u30bf\u30de\u30d6\u306b\u95a2\u3057\u3066\u30bd\u30d3\u3068\u63d0\u643a"},"content":{"rendered":"<p><a href=\"https:\/\/www.innate-pharma.com\/\">\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de<\/a> SA \u304a\u3088\u3073 Swedish Orphan Biovitrum AB (publ) (<a href=\"https:\/\/www.sobi.com\/en\">\u30bd\u30d3<\/a>\uff09\u306f\u672c\u65e5\u3001\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\uff08CTCL\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305fTELLOMAK-3\u78ba\u8a8d\u7b2c3\u76f8\u8a66\u9a13\u306e\u958b\u59cb\u3092\u53ef\u80fd\u306b\u3059\u308b\u305f\u3081\u3001\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u306f\u3001CTCL\u306e\u4e9c\u578b\u3067\u3042\u308b\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u8fc5\u901f\u627f\u8a8d\u7533\u8acb\u306b\u5411\u3051\u305f\u91cd\u8981\u306a\u4e00\u6b69\u3068\u306a\u308a\u307e\u3059\u3002.<\/p>\n<p>\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u30a4\u30cd\u30a4\u30c8\u793e\u306f\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2cIII\u76f8\u78ba\u8a8d\u8a66\u9a13\u300cTELLOMAK-3\u300d\u3092\u5b9f\u65bd\u3057\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u65e9\u671f\u627f\u8a8d\u7533\u8acb\u3092\u652f\u63f4\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002 \u8a08\u753b\u3055\u308c\u3066\u3044\u308bTELLOMAK-3\u8a66\u9a13\u306f\u3001\u305d\u306e\u5f8c\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u304a\u3088\u3073\u6700\u3082\u4e00\u822c\u7684\u306a\u4e9c\u578b\u3067\u3042\u308b\u83cc\u72b6\u606f\u8089\u816b\u306b\u3064\u3044\u3066\u3001\u4e3b\u8981\u306a\u7ba1\u8f44\u533a\u57df\u306b\u304a\u3051\u308b\u5b8c\u5168\u627f\u8a8d\u7533\u8acb\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002Sobi\u793e\u306f\u3001\u65e9\u671f\u627f\u8a8d\u304c\u5f97\u3089\u308c\u305f\u5834\u5408\u3001\u30e9\u30af\u30bf\u30de\u30d6\u306e\u5168\u4e16\u754c\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u306a\u5546\u696d\u5316\u6a29\u3092\u53d6\u5f97\u3057\u3001\u7b2c3\u76f8\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u305f\u5834\u5408\u306b\u306f\u3001\u5168\u4e16\u754c\u306b\u304a\u3051\u308b\u5b8c\u5168\u306a\u958b\u767a\u6a29\u3092\u5f15\u304d\u7d99\u3050\u8cc7\u683c\u3092\u5f97\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002 \u672c\u53d6\u5f15\u306e\u5b8c\u4e86\u306f\u3001\u53d6\u5f15\u306b\u95a2\u9023\u3059\u308b\u72ec\u5360\u7981\u6b62\u6cd5\u4e0a\u306e\u627f\u8a8d\u306e\u53d6\u5f97\u3092\u542b\u3080\u3001\u5b8c\u4e86\u6761\u4ef6\u3092\u6e80\u305f\u3059\u3053\u3068\u3092\u6761\u4ef6\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<h3>\u30e9\u30af\u30bf\u30de\u30d6\u306b\u3064\u3044\u3066<\/h3>\n<p>\u30e9\u30af\u30bf\u30de\u30d6\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306e\u6297KIR3DL2\u6297\u4f53\u3067\u3042\u308a\u3001\u73fe\u5728\u3001\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\uff08CTCL\uff09\u3092\u5bfe\u8c61\u306b\u958b\u767a\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002 CTCL\u306f\u3001\u5e0c\u5c11\u306a\u975e\u30db\u30b8\u30ad\u30f3\u30ea\u30f3\u30d1\u816b\u306e\u4e00\u7fa4\u3067\u3042\u308a\u3001\u305d\u306e\u4e2d\u306b\u306f\u3001\u5e0c\u5c11\u304b\u3064\u4fb5\u8972\u6027\u306e\u9ad8\u3044\u767d\u8840\u75c5\u578b\u3067\u3042\u308b\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u3084\u3001CTCL\u306e\u4e2d\u3067\u6700\u3082\u4e00\u822c\u7684\u306a\u4e9c\u578b\u3067\u3042\u308b\u83cc\u72b6\u8089\u82bd\u816b\u306a\u3069\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/em-systems-and-good-cycle-systems-merge-systems\/\" rel=\"bookmark\">EM Systems\u793e\u3068Good Cycle Systems\u793e\u304c\u5408\u4f75\u3057\u307e\u3057\u305f<\/a><\/h4>\n<p>\u672c\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001FDA\u304b\u3089\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3001EMA\u304b\u3089\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308bPRIME\u6307\u5b9a\u3001\u7c73\u56fd\u304a\u3088\u3073EU\u306e\u4e21\u65b9\u304b\u3089CTCL\u306b\u5bfe\u3059\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001\u306a\u3089\u3073\u306bFDA\u304b\u3089\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u306e\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u30d6\u30ec\u30fc\u30af\u30b9\u30eb\u30fc\u30fb\u30bb\u30e9\u30d4\u30fc\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002 \u672c\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001\u5c11\u306a\u304f\u3068\u30821\u56de\u306e\u5168\u8eab\u7642\u6cd5\u3067\u594f\u52b9\u304c\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u304a\u3088\u3073\u83cc\u72b6\u606f\u8089\u816b\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3001\u975e\u76f2\u691c\u30fb\u591a\u65bd\u8a2d\u5171\u540c\u30fb\u7121\u4f5c\u70ba\u5316\u8a66\u9a13\u3067\u3042\u308b\u7b2cIII\u76f8\u4e3b\u8981\u8a66\u9a13\u300cTELLOMAK-3\u300d\u306b\u5411\u3051\u3066\u9032\u5c55\u3057\u3066\u3044\u307e\u3059\u3002 \u672c\u8a66\u9a13\u306b\u306f\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u78ba\u8a8d\u30b3\u30db\u30fc\u30c8\u304c\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306f\u6f5c\u5728\u7684\u306a\u65e9\u671f\u627f\u8a8d\u304a\u3088\u3073\u8a66\u9a13\u5b8c\u4e86\u5f8c\u306e\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u5b8c\u5168\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u83cc\u72b6\u771f\u83cc\u75c7\u306b\u304a\u3051\u308b\u767b\u9332\u30b3\u30db\u30fc\u30c8\u3082\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306f\u5b8c\u5168\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u304a\u308a\u3001\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff08PFS\uff09\u3092\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p><strong>\u51fa\u5178\uff1a <a href=\"https:\/\/www.businesswire.com\/\" target=\"_blank\" rel=\"noopener\">\u30d3\u30b8\u30cd\u30b9\u30fb\u30ef\u30a4\u30e4<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Innate Pharma SA\u00a0 and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":37592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[14505,14509,14507,14506,14508],"ppma_author":[205],"class_list":["post-37554","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-international","category-news","category-pharma","tag-fda","tag-innate-pharma","tag-lacutamab","tag-sezary-syndrome","tag-sobi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Licenses Lacutamab to Sobi<\/title>\n<meta name=\"description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Licenses Lacutamab to Sobi\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:57:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Licenses Lacutamab to Sobi","description":"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_locale":"ja_JP","og_type":"article","og_title":"Innate Pharma Licenses Lacutamab to Sobi","og_description":"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_site_name":"itbusinesstoday","article_published_time":"2026-08-10T11:57:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Innate Pharma Partners With Sobi on Lacutamab","datePublished":"2026-08-10T11:57:09+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"wordCount":335,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","keywords":["FDA","Innate Pharma","Lacutamab","S\u00e9zary syndrome","Sobi"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","name":"Innate Pharma Licenses Lacutamab to Sobi","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","datePublished":"2026-08-10T11:57:09+00:00","description":"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","width":1200,"height":800,"caption":"Innate Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Partners With Sobi on Lacutamab"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=37554"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions"}],"predecessor-version":[{"id":37555,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions\/37555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/37592"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=37554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=37554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=37554"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=37554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}